<div id="readability-page-1"><p>Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Intellia Therapeutics today and set a price target of $27.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Foroohar is a 3-star analyst with an average return of <span>3.0%</span> and a 46.39% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Ionis Pharmaceuticals.</p> <p>Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.62.</p></div>

NTLA

<p>Leerink Partners analyst Mani Foroohar reiterated a Buy rating for Intellia Therapeutics, setting a price target of $27.00. Foroohar, a 3-star analyst, has an average return of 3.0% and a 46.39% success rate. Intellia Therapeutics has a Moderate Buy consensus with a price target of $16.62.</p>

Intellia Therapeutics (NTLA) Receives a Buy from Leerink Partners